Sharbat v. Iovance Biotherapeutics, Inc.

District Court, S.D. New York·Decided May 9, 2024·No. 1:20-cv-01391·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK SOLOMON SHARBAT, SOLOMON CAPITAL LLC, SOLOMON CAPITAL 401(K) TRUST, and SHELHAV RAFF, Plaintiffs, OPINION & ORDER – against – 20-cv-1391 (ER) IOVANCE BIOTHERAPEUTICS, INC. f/k/a LION BIOTECHNOLOGIES, INC. f/k/a GENESIS BIOPHARMA, INC., and MANISH SINGH, Defendants. RAMOS, D.J.: Solomon Sharbat, Solomon Capital LLC, Solomon Capital 401(K) Trust, and Shelhav Raff (collectively, “Plaintiffs”) brought this action against Iovance Biotherapeutics (“Iovance”) for the alleged breach of a finder’s fee agreement. Doc. 15 (First Am. Compl.). Following a successful motion for sanctions by Iovance that resulted in the dismissal of all other claims, Plaintiffs’ only remaining claims were for unjust enrichment and indemnity. Doc. 140 (Jan. 4, 2023 Op.) at 40–41. Iovance thereafter moved for summary judgment on those remaining claims (Doc. 184), which the Court granted (Doc. 209). Plaintiffs appealed.1 Doc. 222. Before the Court are Iovance’s (1) submissions for the amount of sanctions, (2) motion for attorney’s fees, and (3) motion to require Plaintiffs to post an appeal bond. Docs. 141, 213, 225. For the reasons set forth below, all three applications are granted.

1 Plaintiffs’ appealed the Court’s decisions granting Iovance’s motions for judgment on the pleadings, for sanctions, and summary judgment, as well as its denying Plaintiffs’ motion to compel and for reconsideration of the same. Although “the filing of a notice of appeal has jurisdictional implications, . . . notwithstanding a pending appeal, a district court retains residual jurisdiction over collateral matters, including claims for attorneys’ fees.” Tancredi v. Metro. Life Ins. Co., 378 F.3d 220, 225 (2d Cir. 2004) (internal citations omitted); accord Neroni v. Becker, 609 F. App’x 690, 692 (2d Cir. 2015). �e Court therefore retains jurisdiction for purposes of deciding the instant motions before the Court. I. BACKGROUND A. Factual Background Sharbat and Raff are in the business of helping corporate clients with fundraising, mergers, and strategic alliances, and making introductions to facilitate those ends. Doc. 188 ¶ 5. Sharbat held a Series 7 securities license until November 2012, when FINRA revoked the license and banned him from participating in the securities industry. Id. ¶ 7. No other plaintiff has ever been licensed to broker securities. Id. ¶¶ 6, 9. Solomon Capital is a limited liability company, and Solomon Capital 401(K) Trust is a qualified retirement trust, for which Sharbat is the trustee. Doc. 15 ¶¶ 4–5. It is not disputed that Solomon Capital and Solomon Capital 401(K) Trust are owned and controlled by Sharbat; they have no employees and conduct no business activities other than holding assets on Sharbat’s behalf. See Doc. 140 at 2. Iovance2 is a publicly traded biotechnology company focused on the development of cancer therapies. Doc. 188 ¶ 1. On June 15, 2012, it signed a contract with MBA Holdings, LLC (“MBA”) “to act as a finder to seek financing and other strategic relationships” by introducing investors to Iovance who would participate in planned equity financing (“the MBA Agreement”). Id. ¶ 10–11. Plaintiffs were neither direct parties to, nor intended beneficiaries of, the MBA Agreement, contrary to what Plaintiffs claimed. Doc. 140 at 24. Nor are Plaintiffs indemnified parties within the meaning of the MBA Agreement. Doc. 188 ¶¶ 24–25; see also Doc. 186-9 (MBA Agreement) § 4. Plaintiffs claimed that, beginning in 2012, they began to perform pursuant to the MBA Agreement to seek out investors for Iovance.3 Id. ¶ 15. Specifically, Plaintiffs claimed Sharbat introduced two investors who participated in a financing that closed in

Free access — add to your briefcase to read the full text and ask questions with AI

Sharbat v. Iovance Biotherapeutics, Inc., (S.D.N.Y. 2024).

Sharbat v. Iovance Biotherapeutics, Inc. (Sharbat v. Iovance Biotherapeutics, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Simmons v. New York City Transit Authority
575 F.3d 170 (Second Circuit, 2009)
Federal Deposit Insurance Corp. v. Dintino
167 Cal. App. 4th 333 (California Court of Appeal, 2008)
Campbell v. Scripps Bank
93 Cal. Rptr. 2d 635 (California Court of Appeal, 2000)
Blickman Turkus v. Mf Downtown Sunnyvale
76 Cal. Rptr. 3d 325 (California Court of Appeal, 2008)
Tri-Star Pictures, Inc. v. Unger
32 F. Supp. 2d 144 (S.D. New York, 1999)
Berry v. Deutsche Bank Trust Co. Americas
632 F. Supp. 2d 300 (S.D. New York, 2009)
Santisas v. Goodin
951 P.2d 399 (California Court of Appeal, 1998)
Cargill, Inc. v. Souza
201 Cal. App. 4th 962 (California Court of Appeal, 2011)
Adsani v. Miller
139 F.3d 67 (Second Circuit, 1998)
Renwick v. Bennett (In re Bennett)
298 F.3d 1059 (Ninth Circuit, 2002)
In re Petrobras Sec. Litig.
363 F. Supp. 3d 426 (S.D. Illinois, 2019)
In re Relativity Fashion, LLC
565 B.R. 50 (S.D. New York, 2017)
Neroni v. Becker
609 F. App'x 690 (Second Circuit, 2015)
Stillman v. Inservice America Inc.
838 F. Supp. 2d 138 (S.D. New York, 2011)
In re General Electric Co. Securities Litigation
998 F. Supp. 2d 145 (S.D. New York, 2014)